CN118119845A - 冠状病毒传染病的重症化风险的评估方法以及冠状病毒传染病的重症化风险评估试剂盒 - Google Patents

冠状病毒传染病的重症化风险的评估方法以及冠状病毒传染病的重症化风险评估试剂盒 Download PDF

Info

Publication number
CN118119845A
CN118119845A CN202280052365.1A CN202280052365A CN118119845A CN 118119845 A CN118119845 A CN 118119845A CN 202280052365 A CN202280052365 A CN 202280052365A CN 118119845 A CN118119845 A CN 118119845A
Authority
CN
China
Prior art keywords
coronavirus
severe
risk
protein
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280052365.1A
Other languages
English (en)
Chinese (zh)
Inventor
玉田勉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Original Assignee
Tohoku University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC filed Critical Tohoku University NUC
Publication of CN118119845A publication Critical patent/CN118119845A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
CN202280052365.1A 2021-07-29 2022-03-08 冠状病毒传染病的重症化风险的评估方法以及冠状病毒传染病的重症化风险评估试剂盒 Pending CN118119845A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021124390 2021-07-29
JP2021-124390 2021-07-29
PCT/JP2022/009911 WO2023007809A1 (ja) 2021-07-29 2022-03-08 コロナウイルス感染症の重症化リスクの評価方法、およびコロナウイルス感染症の重症化リスク評価キット

Publications (1)

Publication Number Publication Date
CN118119845A true CN118119845A (zh) 2024-05-31

Family

ID=85087768

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280052365.1A Pending CN118119845A (zh) 2021-07-29 2022-03-08 冠状病毒传染病的重症化风险的评估方法以及冠状病毒传染病的重症化风险评估试剂盒

Country Status (4)

Country Link
US (1) US20250093335A1 (https=)
JP (1) JPWO2023007809A1 (https=)
CN (1) CN118119845A (https=)
WO (1) WO2023007809A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111999503B (zh) * 2020-05-28 2022-05-20 首都医科大学附属北京地坛医院 一组用于预测急性病毒性呼吸道传染病重症化的标志物及其应用和试剂盒
CN112034187B (zh) * 2020-06-04 2022-05-20 北京臻知医学科技有限责任公司 一组预测2019冠状病毒病细胞因子和血栓风暴的标志物及应用和试剂盒
CN114051536A (zh) * 2020-06-12 2022-02-15 国际宇宙医疗株式会社 利用血液中rna的covid-19重症化预测方法
WO2021255900A1 (ja) * 2020-06-18 2021-12-23 国立研究開発法人国立国際医療研究センター 新型コロナウイルス感染者の重症化リスクの検査方法、その検査キット、コンパニオン診断薬及びその重症化リスクマーカー
EP4223887A4 (en) * 2020-10-02 2024-10-30 ISM Co., Ltd. METHODS FOR PREDICTING COVID-19 EXAGGERATION USING BLOOD EXOSOME PROTEIN MARKERS
JP7563940B2 (ja) * 2020-10-22 2024-10-08 シスメックス株式会社 呼吸器感染症に関する情報の取得方法、バイオマーカーの測定値のモニタリング方法、試薬キット、呼吸器感染症に関する情報の取得装置及びコンピュータプログラム

Also Published As

Publication number Publication date
WO2023007809A1 (ja) 2023-02-02
JPWO2023007809A1 (https=) 2023-02-02
US20250093335A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
Oyaert et al. Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients
Slot et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak
Ripperger et al. Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure
Tantuoyir et al. Serological tests for COVID‐19: Potential opportunities
Sermet-Gaudelus et al. Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children, France, April to June 2020
Demaret et al. Severe SARS‐CoV‐2 patients develop a higher specific T‐cell response
Shi et al. Dynamic characteristic analysis of antibodies in patients with COVID-19: a 13-month study
Rümke et al. Impaired SARS-CoV-2 specific T-cell response in patients with severe COVID-19
WO2022049600A1 (en) Methods for assessing t cell-specific immune response against sars-cov-2, and implementations thereof
Al-Mughales et al. Monitoring specific IgM and IgG production among severe COVID-19 patients using qualitative and quantitative immunodiagnostic assays: a retrospective cohort study
DK2678683T3 (en) METHOD FOR forecasting PROGRESSION OF HIV DISEASE
Shen et al. Relationship between the dynamic changes of serum 2019-nCoV IgM/IgG and patient immunity after 6 month hospital discharge
CN118119845A (zh) 冠状病毒传染病的重症化风险的评估方法以及冠状病毒传染病的重症化风险评估试剂盒
HAMADIEN et al. Induction of the trypanosome lymphocyte‐triggering factor (TLTF) and neutralizing antibodies to the TLTF in experimental African trypanosomiasis
Nantanee et al. Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance
Santos et al. COVID-19 recurrence is related to disease-early profile T cells while detection of anti-S1 IgG is related to multifunctional T cells
Olaleye et al. High seroprevalence of SARS-COV-2 antibody before covid-19 vaccination in Nigerian communities
Hussein Correlation of CCL2, CCL5 and CXCL10 Chemokines with Disease Severity among Patients with COVID-19 Infection
Meyer et al. Humoral immune response to COVID-19 vaccines in onchocerciasis-infected individuals: a field study from Ghana
EP3848389A1 (en) Specific monoclonal antibody against the n antigen of human respiratory syncytial virus (hrsv) useful for treating infection, detection thereof and diagnosis
Das et al. Antibody response after a single dose of BBV152 vaccine negatively correlates with pre-existing antibodies and induces a significant but low levels of neutralizing antibodies to Omicron variant
KR102736362B1 (ko) 코로나바이러스 감염증 진단용 조성물
TOYGAR DENİZ et al. Evaluation of Point-of-care and Traditional ELISA Techniques for the Detection of Anti-SARS-CoV-2 IgG Antibodies in Individuals Vaccinated Against COVID-19
Gupalova et al. The Effects of Past COVID-19 and Vaccination on Antibody Levels, Cellular Immunity, and Cytokine Production by Peripheral Blood Mononuclear Cells
Barrios del Pino et al. A novel application of delayed-type hipersensitivity reaction to measure cellular immune response in SARS-CoV-2 exposed individuals.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination